SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PRME reported Q2 2026 results. The stock moved +10.3% on the print.
PRMEearnings

Earnings reactions, page 3

Prime Medicine, Inc. (PRME) Q2 FY2026 earnings

November 11, 2026 · SharpeIQ Research Desk

Reported results

  • The company reported cash, cash equivalents, investments and restricted cash of $108.8 million as of June 30, 2026.
  • The company holds 10 U.S. and 21 ex-U.S. issued patents related to its Prime Editing platform.
  • The company reported that its Prime Editing technology has the potential to address approximately 90% of genetic diseases.
  • The company reported that the six most common mutations for Wilson disease account for up to 26,000 patients in addressable markets.
  • The company reported that approximately 200,000 patients in the US and EU have Alpha-1 Antitrypsin Deficiency.

Guidance

  • The company plans to submit a BLA for PM359 in CGD in the first half of 2027.
  • The company anticipates initial clinical data for PM577a in 2027.
  • The company anticipates initial clinical data for PM647 in 2027.
  • The company expects its cash runway to extend into 2027.

Price and volatility reaction

The stock moved +10.3% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release3.92026-11-10
Close after release4.32026-11-11
Realised move+10.3%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →